Semaglutide Treatment for Alcohol Use Disorder After Metabolic and Bariatric Surgery: A Pilot Randomized Controlled Trial

Registration

Registration

NCT07223983

Study type

INTERVENTIONAL

Allocation

RANDOMIZED

Phase

PHASE1

Masking

SINGLE

Status

ACTIVE_NOT_RECRUITING

Enrollment

4

Start

2026-03-26

Primary completion

2027-02

Lead sponsor

Yale University

Conditions

Alcohol Use Disorder; Weight Loss; Bariatric Surgery Patients

Interventions

DRUG:Semaglutide 1.0 mg

Results posted

FALSE

Individual participant data sharing

NO

Registered primary outcomes

• Percent weight change [Baseline, Week 12, 6-month follow-up]
• Mean drinks per calendar day to assess alcohol use [Baseline, Week 4, Week 8, Week 12, 6-month follow-up]
• Mean drinks per drinking day to assess Alcohol use [Baseline, Week 4, Week 8, Week 12, 6-month follow-up]
• Mean number of heavy drinking days to assess Alcohol use [Baseline, Week 4, Week 8, Week 12, 6-month follow-up]
• Mean number of drinking vs abstinent days to assess Alcohol use [Baseline, Week 4, Week 8, Week 12, 6-month follow-up]